Biogen Idec licenses ALS treatment for up to $345 million
This article was originally published in Scrip
Executive Summary
Biogen Idec has exclusively licensed an oral neuroprotective therapy in Phase II development for the treatment of amyotrophic lateral sclerosis (ALS) from Knopp Neurosciences.
You may also be interested in...
Reformulation Specialist Lipella Eyes $7m Injection From IPO
With a focus on developing novel drugs by reformulating the active agents in existing generics and optimizing these reformulations for new applications, Lipella is set to emerge as a public company.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.